|By Marketwired .||
|June 24, 2014 06:05 AM EDT||
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/24/14 -- Cannabis Technologies Inc. (CSE: CAN)(OTCQB: CANLF) is pleased to announce its first therapy, CT1-085, which is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma.
Cannabis Technologies Inc. has identified our lead composition (CTI 085) through 12 months of discovery and preclinical studies that showed efficacy in lowering intraocular pressure (IOP) in animal models. Cannabinoids have IOP lowering effects, thus, they have therapeutic potential in the treatment of glaucoma. Dr Hossain, Chief Scientific Officer states, "Our objective was to develop a safer; cannabis based topical anti-glaucoma formulation without systemic side effects. We are pleased to have successfully completed our pre-clinical trials which are in the process of the clinical development of the formulation".
Craig Schneider, President & CEO states, "The successful discovery & development of CTI-085 demonstrates to the market that our proprietary Cannabinoid Drug Design Platform (CDP) can successfully identify treatments within our proposed target areas. We are looking forward to the continuation of expanding our product pipeline through the utilization of our Platform Technology."
Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/ inflammatory/ infective, Retinal Drugs) - the global ophthalmic drugs market was valued at USD 16 billion in 2012 and is expected to grow at a CAGR of 5.2% from 2013 to 2018, to reach an estimated value of USD 21.6 billion in 2018. Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 - 2018. Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China), technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases.
About Cannabis Technologies ("CTI")
CTI is a biopharmaceutical drug discovery and development company uniquely focused on the pharmacology and therapeutic potential of cannabinoids.
CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain genes responsible for specific diseases.
Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ophthalmic, Cancer & Angiogenesis, and Inflammation, Pain.
ON BEHALF OF THE BOARD
Craig Schneider, President and CEO
For further information, please visit the company's website at www.cannabis-tech.com.
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause Cannabis Technologies actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and Cannabis Technologies disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Dec. 9, 2016 02:15 PM EST Reads: 1,770
Dec. 9, 2016 02:15 PM EST Reads: 803
Dec. 9, 2016 02:15 PM EST Reads: 223
Dec. 9, 2016 02:15 PM EST Reads: 1,285
Dec. 9, 2016 01:30 PM EST Reads: 1,172
Dec. 9, 2016 11:45 AM EST Reads: 7,368
Dec. 9, 2016 11:45 AM EST Reads: 2,238
Dec. 9, 2016 11:45 AM EST Reads: 2,374
Application transformation and DevOps practices are two sides of the same coin. Enterprises that want to capture value faster, need to deliver value faster – time value of money principle. To do that enterprises need to build cloud-native apps as microservices by empowering teams to build, ship, and run in production. In his session at @DevOpsSummit at 19th Cloud Expo, Neil Gehani, senior product manager at HPE, discussed what every business should plan for how to structure their teams to delive...
Dec. 9, 2016 11:45 AM EST Reads: 1,540
"We analyze the video streaming experience. We are gathering the user behavior in real time from the user devices and we analyze how users experience the video streaming," explained Eric Kim, Founder and CEO at Streamlyzer, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 9, 2016 11:45 AM EST Reads: 695
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry’s single source for the cloud. Fusion’s advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including clou...
Dec. 9, 2016 11:30 AM EST Reads: 535
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Dec. 9, 2016 11:30 AM EST Reads: 1,010
"MathFreeOn.com is a line coding platform for engineers and scientists. When they want to solve an engineering problem and they have to use software - they have to pay a lot of money for licenses - but with MathFreeOn you don't have to pay a lot of money. Just go to our site and write the code and you can check the result right away," explained Simon Lee, CMO of MathFreeOn, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Cla...
Dec. 9, 2016 11:21 AM EST Reads: 270
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Dec. 9, 2016 11:00 AM EST Reads: 714
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
Dec. 9, 2016 11:00 AM EST Reads: 741